New drug targets for type 2 diabetes and the metabolic syndrome

Nature

Volumn 414, Issue 6865, 2001, Pages 821-827

  Moller, D E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG PRODUCTS; EPIDEMIOLOGY; GLUCOSE; INSULIN; METABOLISM; MUSCLE; PATHOLOGY;

DRUG TARGETS;

DRUG THERAPY;

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ADENOSINE TRIPHOSPHATASE (POTASSIUM); ALPHA GLUCOSIDASE; GLIBENCLAMIDE; GLUCOSE; INSULIN; INSULIN RECEPTOR; NATEGLINIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; SULFONYLUREA RECEPTOR;

DIABETES; DRUG DEVELOPMENT; EPIDEMIC; LIFESTYLE; METABOLISM;

DRUG TARGETING; DYSLIPIDEMIA; GENETIC ENGINEERING; GLUCOSE METABOLISM; HORMONAL REGULATION; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FORECASTING; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPID METABOLISM; LIVER; METABOLIC SYNDROME X; OBESITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

ANIMALIA;

EID: 0035857020     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/414821a     Document Type: Review

References (77)

1. Diabetes. Exploding Type II
2. The rising global burden of diabetes and its complications: Estimates and projections by 2010
3. UK prospective diabetes study 33: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications with type 2 diabetes
4. Executive summary of the third report of the National Cholesterol Education Prograto Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
5. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction
6. Pathogenesis of NIDDM: A balanced overview
7. Glucagon physiology and pathophysiology
8. The roles of insulin and glucagon in the regulation of hepitic glycogen synthesis and turnover in humans
9. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus
10. Glucagon antagonists for the treatment of type 2 diabetes
11. Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycemia in moderately streptozotocin-diabetic rats
12. Synthetic peptide antagonists of glucagon
13. Glycogen phosphorylase inhibitors for the treatment of type 2 diabetes mellitus
14. Increased rate of gluconeogenesis in Type II diabetes mellitus: A 13C nuclear magnetic resonance study
15. New approaches in the treatment of type 2 diabetes
16. Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocase
17. Banting Lecture 1990: Beta-cells in type II diabetes mellitus
18. The glucagon-like peptides
19. Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide knockout mice
20. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans
21. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26
22. Single dose treatment of diabetic patients by the DP IV inhibitor P32/98
23. Inhibition of DPPIV by NVP DPP728 improves metabolic control over a 4 week period in type 2 diabetes
24. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice
25. Oral vanadyl sulphate improves hepatic and peripheral insulin sensitivity in patients with non-insulin dependent diabetes mellitus
26. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene
27. Treatment of Zucker diabetic fatty rats with antisense oligonucleotide to phosphotyrosine phosphatase-1B for 5 weeks halts development of diabetes
28. Signaling specificity - A complex affair
29. Glycogen synthase kinase-3 inhibitors potentiate glucose tolerance and muscle glycogen synthase activity in the Zucker Diabetic Fatty Rat
30. The lipid phosphatase SHIP2 controls insulin sensitivity
31. Reversal of obesity and diet-induced insulin resistance with salicylates or targeted disruption of lkkβ
32. Prevention of fat-induced insulin resistance by salicylate
33. Potential role of TNFα in the pathogenesis of insulin resistance and type II diabetes
34. Cellular mechanisms of insulin resistance
35. Obesity and the regulation of energy balance
36. Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur
37. Targeted disruption of the melanocortin-4 receptor results in obesity
38. Central melanocortin receptors regulate insulin action
39. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors
40. What if Minkowski had been ageusic? An alternative angle on diabetes
41. Malonyl-CoA, fuel sensing, and insulin resistance
42. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: A 1H NMR spectroscopy study
43. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM
44. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice
45. Liporegulation in diet-induced obesity: The antisteatotic role of hyperleptinemia
46. The AMP-activated protein kinase, a metabolic master switch: Possible roles in type 2 diabetes
47. Role of AMP-activated protein kinase in mechanism of metformin action
48. AMP activated protein kinase: A critical signaling intermediary for exercise-stimulated glucose uptake?
49. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle
50. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2
51. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice
52. The adipocyte-secreted protein Acrp 30 enhances hepatic insulin action
53. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity
54. The PPARs: From orphan receptors to drug discovery
55. Peroxisome proliferator-activated receptor (PPAR)γ agonists for diabetes
56. Studies on antidiabetic agents. Synthesis of 5-[4-(1-methylcyclohexylmethoxy) benzyl]thiazolidine-2,4-dione (AD-3878) and its derivatives
57. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ
58. Mechanism of PPAR action
59. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat
60. Gene expression profile of adipocyte differentiation and its regulation by PPARγ agonist
61. The hormone resistin links obesity to diabetes
62. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor γ activation has coordinate effects on gene expression in multiple insulin-sensitive tissues
63. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor γ agonists
64. β-hydroxysteroid dehydrogenase Type I - A tissue-specific amplifier of glucocorticoid action
65. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte IIβ-hydroxysteroid dehydrogenase type 1 expression and activity
66. Induction of Acrp30 levels by PPARγ agonists: A potential mechanism of insulin sensitization
67. Putative biomarkers to discriminate the PPARα/γ effects of fenofibrate and rosiglitazone in normal volunteers
68. Cloning and characterization of a functional peroxisome proliferator activator receptor-gamma-responsive element in the promoter of the CAP gene
69. Conclusions from the VA-IIIT study
70. Peroxisome proliferator-activated receptor α activators improve insulin sensitivity-and reduce adiposity
71. Peroxisome proliferator-activated receptor-α activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats
72. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: Effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats
73. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens